Teva’s Ajovy (fremanezumab) Receives NICE Positive Recommendation for Prevention of Migraine in Adults

 Teva’s Ajovy (fremanezumab) Receives NICE Positive Recommendation for Prevention of Migraine in Adults

Teva’s Ajovy (fremanezumab) Receives NICE Positive Recommendation for Prevention of Migraine in Adults

Shots:

  • NICE has recommended Ajovy in its final appraisal document (FAD) to prevent migraine in patients with chronic migraine who have not responded to at least three prior preventive drug treatments
  • The recommendation is based on a dossier submitted to NICE for a single technology appraisal (STA). Following the issuance of the FAD, NICE will provide its formal guidance to the NHS
  • Ajovy is the first and only anti-CGRP therapy, approved in the US and EU, indicated for the treatment of migraine, offering both quarterly and monthly dosing options and is currently under development in Japan by Otsuka, in accordance with a 2017 licensing agreement signed b/w the companies

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Teva

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post